Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized dose-ranging PK/PD study of Tysabri in healthy volunteers
NL-OMON46349Active, not recruiting
- Sponsor
- Bioeq AG
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of natalizumab in multiple sclerosis (MS) and Crohn's disease (3 arms), sponsored by Bioeq AG. Primary endpoints: Pharmacokinetics, Pharmacodynamics and 1 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)Crohn's disease
Beyond the preview
Go deeper on NL-OMON46349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46349.